Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oramed, a wholly owned Israeli subsidiary of Oramed Pharmaceuticals, has received government grant of NIS2m (approximately $540,000) in Israel.
Subscribe to our email newsletter
The funds will be used to support R&D and clinical studies on the company’s oral insulin capsule and oral GLP-1 analog from December 2011 to November 2012.
Oramed Pharmaceuticals CEO Nadav Kidron said, "This grant will greatly assist in covering costs for our upcoming FDA-approved Phase 2 trials on our oral insulin, and aid in the advancement of bringing our breakthrough technology to market."
The Office of the Chief Scientist at the Ministry of Industry, Trade and Labour of Israel has awarded the grant.